Highlights
- EBR Systems shares trading higher on 14 Jan following recent operational disclosures.
- Implant activity increased quarter-on-quarter under pilot and limited market programs.
- Analyst coverage reiterated with updated valuation and maintained speculative rating.
EBR Systems, Inc. (ASX:EBR) is a medical device company focused on the development of the WiSE® CRT System, a leadless and wireless cardiac resynchronization therapy designed for patients with heart rhythm disorders. The system delivers left ventricular endocardial pacing without the use of traditional leads or wires.
The company conducts clinical development and intellectual property activities through subsidiaries based in Australia and the United Kingdom, supporting regulatory and commercialization efforts across multiple markets.
Shares Advance Amid Recent Disclosures
On 14 January 2026, shares of EBR Systems traded at AUD 1.11, reflecting a daily increase of 5.71%. Over the past 5 day, the stock recorded gains of 19.35%, while year-to-date performance stood at an increase of 21.98%.
The share price movement followed recent updates outlining commercial procedures, clinical activity, and revenue expectations for the December 2025 quarter.
Analyst Review Reiterated
EBR Systems remains under limited analyst coverage. The most recent review was issued on 12 January 2026 by David Nayagam of E&P. The analyst reiterated a Speculative Buy rating and assigned a price target of AUD 146.67.
The review referenced broadly positive institutional sentiment toward the company, while noting variations in conviction levels and the relatively limited depth of historical coverage.
Implant Volumes Increase During Q4
On 12 January 2026, EBR Systems reported commercial and clinical progress for the quarter ended 31 December 2025. During Q4, WiSE® System implant volumes doubled compared with the previous quarter.
A total of 18 commercial procedures were completed during the period, bringing cumulative implants to 30 across pilot and Limited Market Release programs.
Commercial Footprint Expands
During the quarter, EBR Systems signed nine new purchase agreements, increasing the number of healthcare facilities with access to the WiSE® System. The company also trained 11 additional physicians, expanding the pool of clinicians qualified to perform implant procedures.
Revenue Guidance and Study Milestones
Based on preliminary unaudited results, EBR Systems expects Q4 2025 revenue in the range of USD 870,000 to USD 935,000, with full-year 2025 revenue projected between USD 1.55 million and USD 1.62 million.
Clinical developments included the initiation of the WiSE-UP post-approval study, with early patient enrolments recorded. The company also treated its first patient in the Totally Leadless CRT (TLC-AU) feasibility study in Australia.






Please wait processing your request...